Organigram Global Inc. announced the accelerated integration of Sanity Group GmbH, appointing Finn Age Hänsel as President, Rest of World & Chief Strategy Officer and Adrian Frenzel as Global Chief Operating Officer. The company amended its share purchase agreement to replace the performance-based earnout with a fixed earnout valued at 85% of the maximum, totaling €102 million consisting of €20 million in cash and approximately €76 million in shares. Payment is due by May 1, 2027, subject to a share price floor of C$3.00 and cap of C$4.00. Sanity contributed approximately CAD$40 million to consolidated net revenue in the most recent quarter, representing over 35% of net revenue. Organigram Global Inc. operates in the cannabis industry, focusing on cultivation, processing, and international expansion.

Organigram Global Inc. announced the accelerated integration of Sanity Group GmbH under a unified global operating structure and amended its share purchase agreement to replace the performance-based earnout with a fixed earnout valued at 85% of the maximum original amount. The amendment requires €20 million in cash and approximately €76 million in shares, payable by May 1, 2027, based on a VWAP calculation subject to a C$3.00 floor and C$4.00 cap. Organigram appointed Finn Age Hänsel as President, Rest of World & Chief Strategy Officer, and Adrian Frenzel as Global Chief Operating Officer. Sanity contributed approximately CAD$40 million to consolidated net revenue in the most recent quarter, representing over 35% of total net revenue, and was accretive to Adjusted EBITDA. Organigram Global Inc. operates in the cannabis industry, producing high-quality cannabis for adult consumers and expanding its global footprint through cultivation, processing, and international commercial platforms.

Organigram Global Inc. reported net revenue of CAD 105.8 million for Q3 Fiscal 2026, a 49% increase from the prior year period, driven by the acquisition of Sanity Group and domestic recreational sales growth. The company posted net income of CAD 105.5 million, primarily due to a CAD 105.8 million fair value gain on Preferred Shares issued to British American Tobacco (BAT), which increased its ownership to approximately 48%. Adjusted EBITDA rose 136% to CAD 13.4 million. The company also recognized a CAD 5.8 million impairment charge related to its U.S. hemp-derived products business, which is being wound down due to regulatory changes effective November 2026. Organigram operates in the cannabis industry, cultivating and producing consumer packaged goods containing cannabis for domestic and international markets.

Organigram Global Inc. provided a business update on July 20, 2026, reporting that its acquisition of Sanity Group GmbH has maintained an average market share of approximately 10% in Germany since April 15, 2026. In Canada, the company holds leading positions in flower (12.5% share) and vapes (14.5% share), with an overall Canadian recreational cannabis market share of 11.1% as of June. The company expects to report Q3 Fiscal 2026 financial results on August 11, 2026, and will host a Digital Investor Session in late September 2026. Organigram is a cannabis company that cultivates and processes cannabis for adult consumers and medical markets.